Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 19/20 | 0.48 |
| ▸ | EDNRB | P24530 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7048685 | 0.89 | EDNRA (0.60) | EDNRAEDNRB | |
| SCHEMBL7050601 | 0.88 | EDNRA (0.49) | EDNRAEDNRB | |
| SCHEMBL7047808 | 0.87 | EDNRA (0.53) | EDNRAEDNRB | |
| SCHEMBL7046702 | 0.87 | EDNRA (0.47) | EDNRAEDNRB | |
| SCHEMBL7047200 | 0.86 | EDNRA (0.56) | EDNRAEDNRB | |
| SCHEMBL7050927 | 0.85 | EDNRA (0.51) | EDNRAEDNRB | |
| SCHEMBL7048774 | 0.84 | EDNRA (0.50) | EDNRAEDNRB | |
| SCHEMBL7049154 | 0.84 | EDNRA (0.67) | EDNRAEDNRB | |
| SCHEMBL7047815 | 0.83 | EDNRA (0.49) | EDNRAEDNRB | |
| SCHEMBL7949358 | 0.82 | EDNRA (0.59) | EDNRAEDNRBKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6632829-B2 | Thienyl, furyl and pyrrolyl-sulfonamides, useful for treating hypertension, cardiovascular disease, asthma, pulmonary hypertension, inflammatory diseases, vision defects, menstrual disorders, renal failure and other diseases | TEXAS BIOTECHNOLOGY CORP. | 2003-10-14 | — | — | US | claimed |
| US-6420567-B1 | PRODRUGS | TEXAS BIOTECHNOLOGY CORPORATION | 2002-07-16 | — | — | US | claimed |
| US-20030208084-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS INC. | 2003-11-06 | — | — | US | disclosed |
| US-6632829-B2 | Thienyl, furyl and pyrrolyl-sulfonamides, useful for treating hypertension, cardiovascular disease, asthma, pulmonary hypertension, inflammatory diseases, vision defects, menstrual disorders, renal failure and other diseases | TEXAS BIOTECHNOLOGY CORP. | 2003-10-14 | — | — | US | disclosed |
| US-20020091272-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS INC. | 2002-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030208084-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | EDNRA, EDNRB, ECE1 | EDNRA 1/4885EDNRB 2/4885KDM4E 2082/4885 |
| US-20020091272-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | EDNRA, EDNRB, ECE1 | EDNRA 1/4885EDNRB 2/4885KDM4E 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.